Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 19;32(9):995–1005. doi: 10.1091/mbc.E20-12-0784

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Way et al. “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.

This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License.

PMC Copyright notice

FIGURE 4: — Validating Cell Health models to Cell Painting data from The Drug Repurposing Hub. The models were not trained using the Drug Repurposing Hub data. (a) The results of the dose alignment between the PRISM assay and the Drug Repurposing Hub data. This view indicates that there was not a one-to-one matching between perturbation doses. (b) Comparing viability estimates from the PRISM assay to the predicted number of live cells in the Drug Repurposing Hub. The PRISM assay estimates viability by measuring barcoded A549 cells after an incubation period. (c) Drug Repurposing Hub profiles stratified by G1 cell count and ROS predictions. Bortezomib and MG-132 are proteasome inhibitors and are used as positive controls in the Drug Repurposing Hub set; DMSO is a negative control. We also highlight all PLK inhibitors in the dataset. (d) HMN-214 is an example of a PLK inhibitor that shows strong dose response for G1 cell count predictions. (e) Tubulin and aurora kinase inhibitors are predicted to have a high number of gH2AX spots in G1 cells compared to other compounds and controls. (f) Barasertib (AZD1152) is an aurora kinase inhibitor that is predicted to have a strong dose response for the number of gH2AX spots in G1 cells predictions.